Enhancing tumor-targeting monoclonal antibodies therapy by PARP inhibitors

被引：7

作者：

Yelamos, Jose ^{[1
,2
,3
]}

Galindo, Miguel ^{[1
]}

Navarro, Judith ^{[1
]}

Albanell, Joan ^{[1
,4
]}

Rovira, Ana ^{[1
,4
]}

Rojo, Federico ^{[1
,5
]}

Oliver, Javier ^{[6
]}

机构：

[1] Hosp del Mar, Canc Res Program, Med Res Inst IMIM, Barcelona, Spain

[2] Hosp del Mar, Dept Immunol, Barcelona, Spain

[3] Ctr Invest Biomed Red Enfermedades Hepat & Digest, Madrid, Spain

[4] Hosp del Mar, Dept Oncol, Barcelona, Spain

[5] IIS Fdn Jimenez Diaz, Dept Pathol, Madrid, Spain

[6] Inst Parasitol & Biomed Lopez Neyra, Dept Cell Biol & Immunol, Granada, Spain

来源：

ONCOIMMUNOLOGY | 2016年 / 5卷 / 01期

关键词：

Apo2L/TRAIL; EGFR; HER2; monoclonal anti-body; PARP; VEGF; GROWTH-FACTOR RECEPTOR; DNA-DAMAGE RESPONSE; NEGATIVE BREAST-CANCER; POLY(ADP-RIBOSE) POLYMERASE-1; PHARMACOLOGICAL INHIBITION; HOMOLOGOUS RECOMBINATION; ACQUIRED-RESISTANCE; IN-VIVO; ACTIVATION; REPAIR;

D O I：

10.1080/2162402X.2015.1065370

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Monoclonal antibodies (mAbs) have become a successful therapeutic approach in cancer. However, some patients do not achieve long-term clinical benefit and most mAbs only exert modest effects as monotherapies. Therefore, combinations with chemotherapy are currently being investigated. Emerging studies have shown a synergistic therapeutic effect of PARP inhibitors and mAbs in cancer. PARP enzymes catalytically cleave beta-NAD(+) and transfer the ADP-ribose moiety to acceptor proteins, modifying their function. In here, we update recent data about the therapeutic effect of the combination of PARP inhibitors with mAbs in cancer treatment and discuss the molecular mechanisms involved in this synergy.

引用

页数：9

共 50 条

[21] High FcγR Expression on Intratumoral Macrophages Enhances Tumor-Targeting Antibody Therapy
Benonisson, Hreinn
Sow, Heng Sheng
Breukel, Cor
Claassens, Jill
Brouwers, Conny
Linssen, Margot M.
Fransen, Marieke F.
Sluijter, Marjolein
Ossendorp, Ferry
van Hall, Thorbald
Verbeek, J. Sjef
JOURNAL OF IMMUNOLOGY, 2018, 201 (12) : 3741 - 3749
[22] Combined PARP inhibitors and small molecular inhibitors in solid tumor treatment (Review)
Jin, Ning
Xia, Yu
Gao, Qinglei
INTERNATIONAL JOURNAL OF ONCOLOGY, 2023, 62 (02)
[23] 7Synthetic lethal targeting of oncogenic transcription factors in acute leukemia by PARP inhibitors
Esposito, Maria Teresa
Zhao, Lu
Fung, Tsz Kan
Rane, Jayant K.
Wilson, Amanda
Martin, Nadine
Gil, Jesus
Leung, Anskar Y.
Ashworth, Alan
So, Chi Wai Eric
NATURE MEDICINE, 2015, 21 (12) : 1481 - +
[24] Synthetic Lethality and Cancer Therapy: Lessons Learned from the Development of PARP Inhibitors
Lord, Christopher J.
Tutt, Andrew N. J.
Ashworth, Alan
ANNUAL REVIEW OF MEDICINE, VOL 66, 2015, 66 : 455 - 470
[25] Understanding and overcoming resistance to PARP inhibitors in cancer therapy
Dias, Mariana Paes
Moser, Sarah C.
Ganesan, Shridar
Jonkers, Jos
NATURE REVIEWS CLINICAL ONCOLOGY, 2021, 18 (12) : 773 - 791
[26] Clinical development of HER3-targeting monoclonal antibodies: Perils and progress
Jacob, Wolfgang
James, Ian
Hasmann, Max
Weisser, Martin
CANCER TREATMENT REVIEWS, 2018, 68 : 111 - 123
[27] Recombinant Monoclonal Antibodies, from Tumor Targeting to Cancer Immunotherapy: A Critical Overview
Mach, J-P.
MOLECULAR BIOLOGY, 2017, 51 (06) : 887 - 899
[28] Recent advances in tumor-targeting anticancer drug conjugates
Jaracz, S
Chen, J
Kuznetsova, LV
Ojima, L
BIOORGANIC & MEDICINAL CHEMISTRY, 2005, 13 (17) : 5043 - 5054
[29] Monoclonal Antibodies, Small Molecule Inhibitors and Antibody-drug Conjugates as HER2 Inhibitors
Li, Xiu-Fang
Liu, Chen-Fu
Rao, Guo-Wu
CURRENT MEDICINAL CHEMISTRY, 2021, 28 (17) : 3339 - 3360
[30] Selective PARP1 inhibitors, PARP1-based dual-target inhibitors, PROTAC PARP1 degraders, and prodrugs of PARP1 inhibitors for cancer therapy
Peng, Xiaopeng
Pan, Wanyi
Jiang, Feng
Chen, Weiming
Qi, Zetao
Peng, Weijie
Chen, Jianjun
PHARMACOLOGICAL RESEARCH, 2022, 186

← 1 2 3 4 5 →